17,261 trials
Allogeneic Blood and Marrow Transplantation (BMT) · Graft Versus Host Disease
Primary: Number of Participants With Grade ≥3 Toxicities Scored According to the CTCAE Version 4.0. — 0 participants
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 84.6; 96.0; 81.0; 76.0 percentage of participants
Estrogen Receptor Positive Tumor · Breast Cancer
Primary: Percentage of Participants Who Achieved the Target Relative Dose Intensity (RDI) of 85% — 77.6; 90.0 Percentage of participants — p=0.1080
Evidence of Liver Transplantation · Rejection · ALEMTUZUMAB
Primary: Incidence of Post Transplant Lymphoproliferative Disorder (PTLD) — 6 participants
Advanced Non-clear Cell Renal Cell Carcinoma
Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157
Breast Cancer
Primary: Safety: Percentage of Participants With Symptomatic Cardiac Events as Assessed by the Investigator — 0; 2.7; 1.3 percentage of participants
Glioblastoma
Primary: Progression-Free Survival — 7.71 weeks
Neck Pain
Primary: 2 Week Change in Pain Score on a Numeric Rating Scale — 6.39; 20.37; 6.45 units on a scale — p=0.10
Urinary Bladder, Overactive
Primary: Base Study/Part 1: Change From Baseline in Average Daily Micturitions at Week 8 — -1.16; -1.62; -1.61; -1.80 Micturitions — p=0.056
Adenomatous Polyposis Coli
Primary: Change in Duodenal Polyp Burden From Baseline to 6 Months — -8.5; 8.0 mm — p=<0.001
Relapsing Remitting Multiple Sclerosis
Primary: Confirmed Relapse, Annualized Relapse Rate — 0.25; 0.37 relapses per year — p=0.077
Non-small Cell Lung Cancer · Efficacy
Primary: Progression Free Survival (PFS) — 168; 140 day
Invasive Breast Cancer
Primary: Rate of Achievement of Pathological Complete Response (pCR) — 9 pathology specimens from participants
Graft Versus Host Disease · Systemic Scleroderma
Primary: Significant Clinical Response — 9; 10 participants
Primary Insomnia
Primary: Sleep Efficiency (SE) on Night 1 and After 4 Weeks of Treatment — 74.8; 83.3; 84.8; 85.6 percentage of time in bed spent sleeping — p=<0.001